10 unknown, 4 recruiting. 6 Phase 1, 4 Early Phase 1, 3 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 4, Recruiting 2 |
| Early Phase 1 | 4 | Unknown 3, Recruiting 1 |
| Not applicable | 3 | Unknown 3 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow CAR: new trials by email Literature Review of CAR trials Research Report on CAR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases anti-CD19/BCMA CAR NK cells (KN5601-K) - Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 12 | 2025-12-03 | 2026-02-03 |
| ThisCART19A for B-NHL Relapsed After Auto-CAR T ThisCART19A with Dose Level 1, ThisCART19A with Dose Level 2 - CAR, B Cell Lymphoma | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-19 |
| ThisCART19A Bridging to alloHSCT for R/R B-ALL Treatment - CAR, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-11 |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Anti-CD19 CAR T-cells - Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children | Phase 2 | Recruiting | KK Women's and Children's Hospital | 40 | 2022-03-15 | 2023-03-09 |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Recruiting | National University Hospital, Singapore | 20 | 2021-09-08 | 2021-09-14 |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia TAA05 cell injection - CAR, Acute Myeloid Leukemia | Not applicable | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 5 | 2021-07-01 | 2021-11-04 |
| ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Unknown | National University Hospital, Singapore | 40 | 2021-04-28 | 2021-09-09 |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors Chimeric antigen receptor modified γδ T cells - CAR, Malignant Tumors | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 8 | 2020-06-03 | 2021-03-08 |
| TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia Chimeric antigen receptor T cells (car-t) - CAR, Acute Myeloid Leukemia | Not applicable | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 5 | 2019-12-09 | 2021-03-08 |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors Targeting CD276 autologous chimeric antigen receptor T cells - CAR, Solid Tumor | Not applicable | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 5 | 2019-09-01 | 2020-12-31 |
| CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies CD19/CD20 CAR-T cell infusion - CAR | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 30 | 2019-04-19 | 2021-03-08 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression GPC3 and/or TGFβ targeting CAR-T cells - Hepatocellular Carcinoma, Immunotherapy | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2017-07-01 | 2024-06-25 |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. Chimeric antigen receptor T cell - Pancreatic Cancer, CAR | Early Phase 1 | Unknown | First Affiliated Hospital of Harbin Medical University | 10 | 2017-06-15 | 2017-08-30 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Myeloid, Acute (2) · Autoimmune Diseases (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Simpson-Golabi-Behmel syndrome (1)
Neoplasms (11) · Hemic and Lymphatic Diseases (9) · Neoplasms by Histologic Type (9) · Hematologic Diseases (8) · Immune System Diseases (7) · Immunoproliferative Disorders (6) · Leukemia (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Leukemia, Lymphoid (5) · Neoplasms by Site (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Leukemia, Myeloid (2) · Lymphoma (2)
Immunotherapy, Adoptive (3) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Therapeutics (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5) · KK Women's and Children's Hospital (2) · National University Hospital, Singapore (2) · The First Affiliated Hospital of Soochow University (2) · First Affiliated Hospital of Harbin Medical University (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · The Children's Hospital of Zhejiang University School of Medicine (1)
China (10) · Singapore (4)
Xingbing Wang (4) · Allen Yeoh, M.D (2) · Dario Campana, M.D, PhD (2) · Aloysius Ho, MD (1) · Michaela Seng, MD (1) · Shui Yen Soh, MD (1) · Wei Yunwei, Dctor (1) · Wing Hang Leung, MD PhD (1) · Zhenfeng Zhang, MD,PhD (1)